Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVUE THERAVISION WITH KETOTIFEN vs ACULAR PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
99% (primarily albumin and alpha-1-acid glycoprotein).
99% bound to plasma proteins, primarily albumin.
2.4 L/kg (high tissue distribution, including ocular tissues).
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
No dosage adjustment required based on renal function; systemic absorption is minimal.
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
None
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Hypersensitivity to ketotifen or any component of the product.
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
None reported.
No known food interactions. No dietary restrictions required.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVUE THERAVISION WITH KETOTIFEN vs ACULAR PRESERVATIVE FREE, answered by our medical review team.
ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVUE THERAVISION WITH KETOTIFEN and ACULAR PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVUE THERAVISION WITH KETOTIFEN and ACULAR PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.